AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18487480
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 200 mg daily
Trial: 18487480
Drug: Fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160 mg plus CoQ 200 mg daily
Trial: 8931744
Drug: Cytarabine 500
RxNorm normalized name: CYTARABINE 500MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine 500 mg/m2 0 h and 12 h, cisplatin 15 mg/m2 6 h and 18 h. Day 2‐4: cisplatin 30 mg/m2. Cycles repeated every 4 weeks
Trial: 1880233
Drug: Estazolam 1
RxNorm normalized name: estazolam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 1 mg
Trial: 1880233
Drug: Estazolam 2
RxNorm normalized name: estazolam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 2 mg and Flurazepam 30 mg
Trial: 7068093
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorhexidine, tramazoline and aluminiumtrilactate (n = 50)
Trial: 31470879
Drug: Phlebotomy (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy (450 mL of whole blood venesection)
Trial: 31470879
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OCs) containing cyproterone acetate (3 months treatment)
Trial: 27842470
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care intervention (delivered by social workers without previous mental health experience, including cognitive-behavioral therapy or facilitated antidepressant medication)
Trial: 21742514
Drug: Turmeric supplementation
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric supplementation (500 mg turmeric, 22.1 mg curcumin, 3 capsules daily for 3 months)
Trial: 21742514
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (starch, identical in color and size to turmeric capsules, 3 capsules daily for 3 months)
Trial: 25151662
Drug: Treatment interventions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interventions
Trial: 15798291
Drug: R(int) measured
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(int) measured at flows <0.3 l s(‐1)
Trial: 12939120
Drug: Chitosan formulation
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan formulation (2100 mg chitosan and 300 mg psyllium husk seeds, six capsules three times daily for three days)
Trial: 9583342
Drug: Preparing for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparing for the Drug‐Free Years Program (PDFY)
Trial: 1854051
Drug: Adenosine triphosphate
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine triphosphate (ATP) at doses of 0.012, 0.025, and 0.05 mg.kg‐1.min‐1
Trial: 6344732
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of subcuticular suture and sterile Micropore tape
Trial: 29870591
Drug: Amenamevir 400
RxNorm normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Amenamevir 400 mg with montelukast 10 mg
Trial: 29870591
Drug: Amenamevir 400
RxNorm normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Amenamevir 400 mg with bupropion 150 mg
Trial: 21194357
Drug: Sitagliptin (DPPIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (DPPIV inhibitor)
Trial: 18651257
Drug: MR arthrography
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR arthrography with Gd-DTPA2- injection and comprehensive imaging (static and dynamic)
Trial: 17050788
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg once daily for 7 days (n = 8)
Trial: 17050788
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg twice daily for 6 days with a single dose on day 7 (n = 8)
Trial: 15727187
Drug: Multiplex nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplex nutritional intervention group (100 g coarse food grain every day and nutrition education)
Trial: 11004017
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-arginine and GHRP-2 (AG)
Trial: 1346342
Drug: Control (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (triple therapy without amiodarone)
Trial: 6088192
Drug: Standard meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard meal with 12 g olive oil
Trial: 6088192
Drug: Standard meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard meal with 36 g olive oil
Trial: 29427024
Drug: linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin (5 mg, once-daily)
Trial: 29427024
Drug: voglibose (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: voglibose (0.9 mg, thrice-daily)
Trial: 12149667
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Trandolapril 0.5 mg/day + Irbesartan 150 mg/day)
Trial: 9539500
Drug: Abciximab (platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (platelet glycoprotein IIb/IIIa inhibitor)
Trial: 9539500
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (control group not explicitly mentioned)
Trial: 337478
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of glycerol (25 g twice daily for 6 days)
Trial: 21684508
Drug: Aspirin 50
RxNorm normalized name: aspirin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 50 mg or 100 mg
Trial: 11334905
Drug: 5% saline
RxNorm normalized name: Breathe Free 0.65% Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% saline infusion on day 3 or 4 after hCG administration in IVF patients
Trial: 11334905
Drug: 5% saline
RxNorm normalized name: Breathe Free 0.65% Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% saline infusion test on day 10 after hCG administration
Trial: 11334905
Drug: 5% saline
RxNorm normalized name: Breathe Free 0.65% Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% saline infusion in controls (normal menstrual cycles)
Trial: 3668801
Drug: intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: 3668801
Drug: oral capsules
RxNorm normalized name: Plenity Oral Capsules
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: 25544247
Drug: Sufentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system
Trial: 25544247
Drug: Sufentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system (40 consecutive doses)
Trial: 25544247
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of sufentanil
Trial: 25544247
Drug: Sufentanil buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil buccal (BU) administration
Trial: 25544247
Drug: Sufentanil oral
RxNorm normalized name: SUFentanil Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil oral (PO) administration
Trial: 25544247
Drug: Sufentanil sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil sublingual (SL) administration
Trial: 22855038
Drug: Total glucosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glucosides of paeony capsule (TGPC), 600 mg per time, three times daily for three months
Trial: 22855038
Drug: Compound glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound glycyrrhizin tablet, 50 mg per time, three times daily for three months
Trial: 20798432
Drug: Stopping antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping antiplatelet agents
Trial: 20798432
Drug: Traditional approach
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional approach of stopping medications up to two weeks before surgery
Trial: 2201721
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg or higher
Trial: 6669631
Drug: Zopiclone 11.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 11.25 mg
Trial: 2201721
Drug: Zopiclone 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 3.5 mg and 7.5 mg
Trial: 2201721
Drug: Zopiclone up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone up to 11.25 mg
Trial: 2201721
Drug: Zopiclone higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone higher doses when well tolerated
Trial: 29020150
Drug: Ceftriaxone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1.0 g, intravenously, once daily for 10 days)
Trial: 29020150
Drug: Benzathine Penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine Penicillin G (2.4 million units, intramuscularly, once weekly for 2 weeks)
Trial: 29020150
Drug: Benzathine Penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine Penicillin G
Trial: 15208051
Drug: Mifepristone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 10 mg weekly
Trial: 15208051
Drug: Mifepristone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 10 mg planned postcoitally
Trial: 9272610
Drug: Therapies that
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies that lower glucose levels
Trial: 30947737
Drug: Intervention practices
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention practices received £1500, a support manual, and four meetings to develop local solutions.
Trial: 16729880
Drug: Joint mobilisation
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint mobilisation twice a week for four weeks
Trial: 9159724
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment for 10 weeks
Trial: 9159724
Drug: Nonspecific psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific psychological treatment (control) for 10 weeks
Trial: 9159724
Drug: Nonspecific psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific psychological treatment (control)
Trial: 8292465
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg quinapril
Trial: 8292465
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg quinapril
Trial: 3541830
Drug: Imipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (up to 5 mg/kg/d)
Trial: 3541830
Drug: Weight-corrected imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-corrected imipramine dosage
Trial: 31910896
Drug: Freeze-dried formulation
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried formulation of Tamalakyadi decoction
Trial: 31910896
Drug: Antihistamine loratadine
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antihistamine loratadine (control)
Trial: 27977600
Drug: Sufentanil 2.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2.0 μg/kg + dexmedetomidine 2.0 μg/kg (group S2)
Trial: 27977600
Drug: Butorphanol 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.15 mg/kg + dexmedetomidine 2.0 μg/kg (group N2)
Trial: 27977600
Drug: Butorphanol 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.15 mg/kg + dexmedetomidine 1.5 μg/kg (group N1)
Trial: 27977600
Drug: Sufentanil 2.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2.0 μg/kg + dexmedetomidine 1.5 μg/kg (group S1)
Trial: 23624699
Drug: Topical APF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical APF gel (1.23 % F, pH 3.5, for 4 min)
Trial: 23624699
Drug: Fluoride +
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride + laser group (F + L)
Trial: 20075768
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for both DS and SPS
Trial: 15533612
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice to eat more oil-rich fish or take LCn3 supplements
Trial: 12812661
Drug: Calmette‐Guerin vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calmette‐Guerin vaccine (BCG) once a week for 8 weeks and then once every month for 8 months
Trial: 11061615
Drug: BIP +
RxNorm normalized name: Buprenorphine and Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIP + RT (bleomycin 30 units/24‐hour infusion, ifosfamide 5 g/m2/24 hours, cisplatin 50 mg/m2 followed by pelvic radiotherapy)
Trial: 9293972
Drug: Captopril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (mean dose 46/69 mg/day after 7 days/4 weeks)
Trial: 23768518
Drug: Mega-dose vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mega-dose vitamin A supplementation (MVAS) of 60 mg administered at diagnosis and again after 1 month.
Trial: 23322206
Drug: FLOT (infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT (infusional 5-FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m²)
Trial: 20626444
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of a gel containing allium cepa, allantoin, and pentaglycan twice a day for 24 weeks
Trial: 20626444
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical treatments
Trial: 16508264
Drug: 36% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36% phosphoric acid gel for 1 min
Trial: 16508264
Drug: 36% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36% phosphoric acid gel for 4 min
Trial: 12953945
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299v in combination with metronidazole
Trial: 12953945
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with metronidazole
Trial: 14564593
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: low loading dose and high demand bolus
Trial: 14564593
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: high loading dose and demand bolus
Trial: 14564593
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: high loading dose and low demand bolus
Trial: 6365104
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg tulobuterol
Trial: 6365104
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg fenoterol
Trial: 30879366
Drug: Continuous probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous probiotics (1 capsule daily for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Trial: 30879366
Drug: Interrupted probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted probiotics (1 capsule twice a week for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Trial: 19770374
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (cisplatin and fluorouracil)
Trial: 15307543
Drug: Molecular Adsorbent
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular Adsorbent Recirculating System (MARS) for 3 consecutive days; continued if bilirubin > 6 mg/dl
Trial: 15307543
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (non-MARS group)
Trial: 9052301
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg) plus ketamine (60 mg) administered preoperatively (Group 1)
Trial: 9052301
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg) plus ketamine (60 mg) administered postoperatively (Group 2)
Trial: 8110072
Drug: rh‐EPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh‐EPO treatment for 12 months
Trial: 8110072
Drug: rh‐EPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh‐EPO treatment for 24 months
Trial: 19058926
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release (SR) methamphetamine (30 mg first pill, 1x/day; 0mg 5x/day)
Trial: 16825088
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E therapy (400 mg daily for 5 weeks)
Trial: 12881929
Drug: 0.18 g
RxNorm normalized name: MENTHOL 0.18 g in 100 TOPICAL GRANULE [Cough Drops]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18 g sucrose
Trial: 12881929
Drug: 0.24 g
RxNorm normalized name: Sodium Fluoride 0.24 g in 100 g DENTAL PASTE [AM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24 g sucrose (2 mL 12% sucrose)
Trial: 7857509
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dried hypericum extract
Trial: 7857509
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg dried hypericum extract
Trial: 7857509
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg dried hypericum extract
Trial: 7857509
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 300 mg/day long-term dosing
Trial: 7857509
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose pharmacokinetics
Trial: 7857509
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of absorption lag-time
Trial: 26341759
Drug: Walk-and-eat intervention
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walk-and-eat intervention (n = 30; nurse-supervised walking three times per week and weekly nutritional advice)
Trial: 9504568
Drug: Interferon-gamma (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma (100 microg) daily by subcutaneous injection for up to 90 days
Trial: 8070510
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg naftopidil
Trial: 24872875
Drug: Individualized manual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized manual therapy and rehabilitative exercise
Trial: 22669400
Drug: Continuous intradermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intradermal absorbable sutures (A)
Trial: 12794785
Drug: Operant pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operant pain treatment group (OTG; n = 40)
Trial: 12794785
Drug: Standardized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized medical program with emphasis on physical therapy (PTG; n = 21)
Trial: 10808734
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (two-week treatment)
Trial: 10808734
Drug: 5-mononitrate 40
RxNorm normalized name: Iso-5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mononitrate 40 mg daily for two weeks
Trial: 10808734
Drug: Propranolol (two-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (two-week therapy)
Trial: 10808734
Drug: Nadolol 40-80
RxNorm normalized name: nadolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 40-80 mg daily for two weeks